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 Executive summary 
 
This short paper aims to identify key evidence gaps in our knowledge of livestock- and 
fisheries-linked antimicrobial resistance in the developing world, and to document on-going 
or planned research initiatives on this topic by key stakeholders. 
 
The antimicrobial resistant (AMR) infections in animals that are of most potential risk to 
human health are likely to be zoonotic pathogens transmitted through food, especially 
Salmonella and Campylobacter. In addition, livestock associated methicillin resistant 
Staphylococcus aureus (LA MRSA) and extended spectrum beta lactamase E. coli (ESBL E. 
coli) are emerging problems throughout the world.  
 
In developing countries, AMR pathogens are commonly found in animals, animal food 
products and agro-food environments, but the lack of surveillance systems means there are 
no reliable national data on the level of AMR in animals and their products. While AMR 
pathogens in animals and their products undoubtedly contribute to AMR infections in 
people, the literature from developing countries is insufficient to draw firm 
conclusions on the extent of this contribution. 
 
The key driver of agriculture-related AMR is the quantity and quality of use of antimicrobials 
in livestock production and aquaculture. We don't have accurate information on antibiotic 
use in developing countries but agricultural use probably exceeds medical use; most use 
is probably in intensive production systems; and, use is probably increasing rapidly.  
 
The underlying driver for antimicrobial use and development of AMR is the livestock and 
aquaculture revolutions, by which is meant the rapid growth in intensive production systems 
in response to increased demand for livestock and fish products. This demand in turn is 
driven by population increases, urbanisation, improving economic conditions and 
globalisation in developing countries and is predicted to continue to increase. Based on 
livestock intensification patterns, China, Brazil and India are current hotspots, and future 
hotspots are Myanmar, Indonesia, Nigeria, Peru and Vietnam. Based on aquaculture trends, 
China is a hotspot and Indonesia, Thailand, Vietnam, Bangladesh, India and Chile are other 
countries where antimicrobial use in fish production may be problematic. 
 
Many interventions using educational, managerial, regulatory and economic approaches to 
improve drug use have been studied. Training by itself is relatively ineffective but if 
combined with strategies to change market conditions (by changing incentives and 
accountability environment) better success has been achieved. There are many animal 
husbandry options that can allow production without non-therapeutic antimicrobials, but 
these options have not been widely used in, or adapted to, developing countries. 
 
In developing countries, there is a dearth of evidence on most aspects of agricultural related 
AMR.  This includes: the use of antimicrobials in agriculture; the impacts of this use on 
human and animal health; the acceptability and feasibility of stricter control of antibiotic use 
in agriculture; and, the costs and benefits of stricter control taking into account trades offs 
between overuse and lack of access to antimicrobial drugs. At the same time, AMR is 
intrinsically a global problem that can only be managed at supra-national scale and the 
current strong momentum to take action on AMR provides an opportunity to address the 
problem globally and comprehensively, addressing both medical and veterinary use. This 
should be done in an evidence-based way which includes filling knowledge gaps, careful 
piloting of interventions, and rigorous evaluation of successes and failures. 
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 SECTION 1 
Introduction 
 
 
Human infections caused by pathogens that have become resistant to the medical drugs 
impose a large burden of illness and death and entail enormous costs. Recent reports 
predict drug resistance will increase substantially, causing millions of extra deaths and 
costing trillions of dollars by mid 21st century (see section 4). While many disease-causing 
organisms show resistance to drugs this report focuses on infections caused by 
bacteria that are potentially linked to agricultural use of antibiotics in developing 
countries.  
 
Bacterial infections in people and animals have been successfully treated with 
antimicrobials1, since the discovery of these drugs in the first half of the 20th century. 
However, the use of antimicrobials in animal agriculture (both livestock and fish production) 
has been debated for decades because of its potential impacts on human health. In recent 
years there is increasing consensus that there are links between veterinary drug use and 
drug resistance in human pathogens, and that it is desirable to reduce antimicrobial use in 
agriculture.   
 
Agriculture is of crucial importance for food security and development. Worldwide, one in 
three people work in agriculture and farming produces 4 billion tonnes of food to feed over 7 
billion people a year. Rising populations in developing countries, alongside increasing 
wealth, urbanisation and changing dietary preferences are driving a dietary revolution, in 
which consumption of eggs, milk, meat and farmed fish is increasing much more rapidly than 
the consumption of staples or pulses. This in turn is driving changes in how animals are 
farmed. Poultry, pig and fish production is increasing fastest, and ever more animals are 
kept in high input-high output intensive systems.  
 
These increases in animal numbers and changes in farming systems, against a background 
of high levels of endemic and epidemic disease would be expected to increase use of 
antibiotics in developing country agriculture. Because the quantity of antibiotics used is the 
main driver of development of resistance to these antibiotics, animal agriculture in 
developing countries could have an increasing role in the development of antimicrobial 
resistant (AMR) pathogens. While discovery of novel antimicrobials would support 
management of infectious bacterial disease into the future, over the last decades there has 
been a dramatic slow-down in the development of new antimicrobials, which increases the 
need to safeguard existing antimicrobials. 
 
The report aims to identify key evidence gaps in our knowledge of livestock- and 
fisheries-linked antimicrobial resistance in the developing world and to document on-
going or planned research initiatives on this topic by key stakeholders. 
 
1 Technically, an antibiotic is a substance produced by a microorganism that at a low concentration inhibits or kills 
other microorganisms and an antimicrobial is any substance of natural, semisynthetic or synthetic origin that kills or 
inhibits the growth of microorganisms (bacteria, virus or other) but causes little or no damage to the host. All 
antibiotics are antimicrobials, but not all antimicrobials are antibiotics. An antibacterial is a substance used to treat 
bacterial infections. However, antibiotic is now more often used to signify antibacterial and is understood by the 
public and professionals this way. In this document, antimicrobial is used but generally refers to antibiotics.  
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SECTION 2 
Key players and initiatives on AMR research 
and management 
 
 
International organisations with an interest in research:  
 
• The World Health Organization (WHO) has been addressing AMR since 2001 and is 
the lead global organisation for tackling AMR. Its numerous activities include 
assessing AMR, capacity building for AMR surveillance, co-ordinating AMR activities, 
and developing strategies and action plans. In 2015 the WHO launched the Global 
Action Plan for AMR. 
• The World Animal Health Organization (OIE) promotes prudent use of veterinary 
drugs, helps harmonise national surveillance programs, and conducts risk 
assessment. It is developing a global database on veterinary drug use. 
• The Food and Agricultural Organization (FAO) has activities on AMR, often as 
tripartite collaborations with WHO and FAO. This includes providing advice, 
improving regulatory frameworks, raising awareness and supporting research to 
generate data. 
• The Codex Alimentarius Commission has a longstanding Committee on Residues of 
Veterinary Drugs in Foods and an ad hoc Intergovernmental Task Force on 
Antimicrobial Resistance. Principal texts include a code of practice to minimize AMR 
and guidelines for risk analysis of foodborne AMR. 
• The CGIAR system conducts agricultural research for poverty alleviation. A new 
CGIAR research program on the human health impacts of agriculture has a cluster of 
activities on antimicrobial use in agriculture. 
 
In addition, many regional actors have an interest in AMR including the European Union, the 
African Union, the Association of Southeast Asian Nations and others. 
 
“Three sisters’ initiatives” for AMR management and understanding 
The ‘three sisters’ can refer to the three sister organisations with a mandate for global health 
(WHO, OIE and FAO) or to the three standard setting organisations recognised by the World 
Trade Organization (the Codex Alimentarius Commission, OIE and International Plant 
Protection Convention). Initiatives on AMR involving WHO, OIE and FAO include: 
 
• The Global Foodborne Infections Network (GFN) is a WHO initiative to build 
laboratory capacity and provides training and reference facilities for AMR pathogens. 
• The WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance 
(WHO-AGISAR) was set up in 2008 to minimize the public health impact of AMR 
associated with the use of antimicrobial agents in all food-producing animals. 
• WHONET is a downloadable, Windows-based database software used for the 
management and analysis of microbiology data, with a special focus on the analysis 
of antimicrobial susceptibility test results. 
• The Antimicrobial Resistance Information Bank (AR InfoBank) provides access to 
policy-makers and health care workers to information about drug resistance and 
resistance surveillance networks. It is collaboration between WHO and WHO 
Collaborating Centre for Electronic Disease Surveillance, INSERM, Paris. 
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 • The FAO/OIE/WHO Tripartite is a formal alliance to enhance collaboration between 
human and animal health and has identified AMR as one of the three priority topics 
for joint actions. 
 
Developing country stakeholders:  
These include public and private health services and veterinary services which use, and in 
the case of public services, regulate antibiotics; food safety authorities concerned with 
antimicrobials as health hazards; research institutes who carry out most of the studies on 
AMR; consumer groups concerned with food safety (but often ineffective); large-scale 
commercial agriculture and aquaculture who are major uses of antimicrobials; NGOs who 
often provide treatments for animals after disasters or in vulnerable communities; and small-
scale farmers who are likely minor users of antimicrobials. 
 
Veterinary pharmaceutical companies and representatives:  
The largest global companies are Zoetis, Merck Animal Health/MSD Animal Health, Bayer 
HealthCare Animal Health Division, Virbac s.a. and Elanco Animal Health.There are many 
veterinary drug manufacturers in developing countries; these tend to produce generic drugs 
and are less organised into groups representing their interests. The International Federation 
for Animal Health (IFAH) represents the animal health industry (but mainly developed world 
companies). Globally, the investment of private pharmaceutical firms into research and 
development is around double the investments of the public sector, and most of this 
investment is for human health products. However, there is very little research into bacterial 
infectious diseases other than tuberculosis. 
 
Other initiatives with a global perspective): 
The following initiatives (in alphabetical order) have a focus on both veterinary use of 
antibiotics and developing countries: 
 
• Antibiotic Action (AA) is a global initiative established by the British Society for 
Antimicrobial Chemotherapy (BSAC) as a forum to identify and implement solutions 
for AMR. 
• Founded in 1981, the Alliance for the Prudent Use of Antibiotics (APUA) is the oldest 
of the organisations devoted to protecting antibiotics. It began including developing 
countries in Latin America and then Africa in its formal network around the turn of the 
21st century.  
• The Global Alliance for Livestock Veterinary Medicines (GALVmed) is a not-for-profit 
public-private partnership that aims to increase availability and access of livestock 
products to poor farmers. It has been working with FAO and IFAH on vet drug 
quality. 
• The Global Antibiotic Resistance Partnership (GARP) is a project funded by the Bill 
and Melinda Gates foundation and implemented by the Center for Disease 
Dynamics, Economics & Policy (Washington). It generates evidence and formulates 
and promotes policy related to antibiotic use and resistance in low and middle 
income countries.  
• The Global Health Security Agenda (GHSA) is a USA government initiative with 12 
action packages, including the Antimicrobial Resistance Action Package. This helps 
develop and implement national action plans for AMR. The initiative is led by Centres 
for Disease Control and Prevention (CDC). 
• The International Surveillance of Reservoirs of Antibiotic Resistance (ISRAR) project 
is coordinated by the Alliance for the Prudent Use of Antibiotics (APUA), to collect 
and analyse environmental and veterinary commensal organisms which may serve 
as reservoirs for AMR. 
• Action on Antibiotic Resistance (ReACT) is an independent global network for 
concerted action on antibiotic resistance. Operating from Uppsala University, 
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Sweden it carries out awareness raising activities in many developing countries and 
supports national working groups. 
• The Review on Antimicrobial Resistance (RAR) is a UK initiative co-funded by, but 
independent of, the UK Government the Wellcome Trust. By the summer of 2016, 
the Review will recommend a package of actions that should be agreed 
internationally.  
• The World Alliance Against Antibiotic Resistance (WAAR) is a non-profit organisation 
comprising a range of stakeholders from over 50 countries which aims to raise 
awareness on antibiotic resistance. 
 
Surveillance networks with a global or developing country focus: 
Many surveillance networks focus on AMR in human pathogens including SENTRY, 
ANSORP and DOMI in Asia. In Africa, Pasteur Institutes in several countries provide well-
functioning laboratories. 
 
Developed country interests:  
These include research institutes, donors, food importing companies, veterinary 
pharmaceutical exporting companies, and government and intergovernmental agencies with 
interests in global AMR. 
 
Organisations that fund research into AMR 
The following organisations were identified by the WHO as providing funding for research on 
AMR and have interests or a mandate for research in developing countries: 
 
• APUA - Alliance for the Prudent Use of Antibiotics 
• Bill and Melinda Gates Foundation 
• European Union 
• Grantsnet 
• ISID - International Society for Infectious Diseases 
• The Wellcome Trust 
• USAID-The United States Agency for International Development 
 
Organisations that fund research into AMR but without a major focus on developing 
countries include: 
 
• CDC - Center for Disease Control in the USA 
• ESCMID - European Society of Clinical Microbiology and Infectious Diseases 
• MRI - Medical Research Council (UK) 
• NIAID - National Institute of Allergy and Infectious Diseases 
• UK Department of Health 
• USDA ARS - United States Department of Agriculture Agricultural Research Service 
• USEPA - The United States Environmental Protection Agency 
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 SECTION 3 
Prevalence of AMR infections in livestock and 
fish systems and products 
 
 
Evidence 
Animal infections caused by AMR pathogens of greatest threat to human health are 
zoonotic pathogens transmitted through food and by direct contact. Among the most 
common zoonotic pathogens transmitted through livestock and food to humans, are non-
typhoidal Salmonella (NTS), Campylobacter, and toxigenic Escherichia coli, (WHO, 2011; 
WHO, 2014).  Livestock are important reservoirs for these three pathogens and AMR is 
widespread especially in Campylobacter and Salmonella. All three are important causes of 
gastro-intestinal illness in developing countries and globally, and are responsible for 27 
million Disability Adjusted Life Years (DALYs)2 annually or 30% of all diarrhoeal DALYs  
(IMHE, 2013). (For comparison, breast cancer has a burden of 12 million DALYs and 
hepatitis 13 million). Less common, but important, zoonotic foodborne pathogens include 
non-cholera Vibrio (NCV) in seafood and Listeria monocytogenes in meat and dairy 
products: their global burden has not been well assessed. 
 
AMR is a problem in these five foodborne pathogens in developing countries and the 
contribution of drug resistant infections to the overall human health burden caused by these 
diseases, while not well quantified, is probably substantial. However, less is known about 
the role that agricultural use of antibiotics plays in the development of this resistance. 
Some studies find high resistance levels in pathogens from human clinical cases, alongside 
low resistance levels to the same antibiotic in pathogens in food-producing animals (or the 
reverse) suggesting bacterial populations are seperate (Luangtongkum et al., 2009). In other 
cases, similar resistance patterns are seen in bacteria isolated from animals, people and the 
environment suggesting shared bacterial populations (Sahoo et al., 2012). 
 
It is highly probable that E. coli and enterococci acquired from animal products are a source 
for resistance plasmids that spread to human adapted E. coli and enterococci, causing 
urinary and wound infections, and septicaemia (EFSA, 2008). The burden of this in 
developing countries is not known. Genes for a type of resistance known as extended 
spectrum beta-lactamase (ESBL) and AmpC beta-lactamase have spread internationally 
over the last decade in strains of E. coli and Salmonella. ESBL is spread mainly by transfer 
of plasmids. The burden of ESBL infections attributable to livestock is not known, but 
the frequent prevalence of ESBL/AmpC producing organisms in farm animals and food 
products suggests they may be the origin of some human infections.  
 
Methicillin resistant Staphylococcus aureus (MRSA) is a major cause of human illness 
worldwide, and is usually acquired directly or indirectly from people. The burden of MRSA 
and the prevalence of LA-MRSA in developing countries is not known. In countries with 
better data it is generally of minor importance compared to hospital or community acquired 
MRSA, except for countries with low levels of MRSA and high levels of pig keeping. In these 
contexts, LA-MRSA infections are usually found in people having contact with pigs (or 
calves). 
2 The Disability Adjusted Life Year (DALY) is widely used and accepted global metric of human sickness 
and death. One DALY can be thought of as one lost year of "healthy" life.  
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We do not have good data on the prevalence of AMR pathogens in livestock and fish 
and their products in developing countries. This is because systematic, national, iterative 
(repeated) surveillance programs are needed to generate good information on AMR in 
livestock, fish and food, and these types of programmes exist only in some EU and north 
American countries (WHO, 2014). 
 
Many individual studies suggest AMR is common in agricultural systems in 
developing countries. There are many academic studies that assess antibiotic residues 
and AMR pathogens in animals, in livestock and fish products, and (to a lesser extent), in  
agro-food environments, and wildlife in developing countries. Drug resistance is found in 
zoonotic and non-zoonotic pathogens (see table 1 for examples). Most studies find 
resistance is common to older, cheaper, widely used antibiotics and often present for newer, 
more expensive drugs, not licensed or rarely used in veterinary medicine. Resistance to 
other veterinary drugs such as trypanocides, insecticides and de-wormers are also 
commonly reported in developing countries. However, many of these studies have quality 
problems: weak methodology (e.g. sampling was not random, detailed 
microbiological methods are not given, no information on quality assurance) and non-
standardised reporting; representative of small populations; and, published only in 
the grey literature. Only a few more recent reviews cover multiple pathogens and countries 
(Mshana et al., 2013; Omulo et al., 2014). Most studies focus on prevalence and 
patterns in single hosts or food types. 
 
Population Disease type / 
pathogen 
Antimicrobial 
Resistance 
Reference 
Older % Newer % 
Free-ranging pigs, Kenya Animal 
(salmonella) 
37 (ampi) 4 (cipro) Onyango et al., 2014 
Urban dairy cows, Ethiopia Zoonoses (NTS) 100 
(ampi) 
0 (cipro) Addis et al., 2011 
Smallholder chicken, 
Nigeria 
Zoonosis (S. 
aureus) 
100 
(ampi) 
0 (cipro) Suleiman et al., 2013 
Intensive chicken, China Zoonosis (E coli) 88 (ampi) 17 (gent) Wang et al., 2013 
Farmed cockles, Malaysian 
coast 
Zoonosis (NCV) 68 (ampi) 0 (cipro) Sahilah et al., 2014 
Salads, retail shops Nigeria Zoonoses 
(Listeria) 
93 (ampi) 4 (cipro) Ransangan et al., 
2013 
Cow dung, India Zoonoses (E. coli) 71 (ampi) 43 (cipro) Sahoo et al., 2012 
Ampi = ampicillin, cipro=ciprofloxacin, gent=gentamicin 
 
Table 1 Examples of studies on antimicrobial resistance in agri-food systems in developing 
countries 
 
The large number and consistency of results make it very likely that AMR pathogens are 
common in animals, animal food products and agro-food environments in developing 
countries, but the literature is insufficient to draw firm conclusions on drivers or 
management of AMR or the contribution of AMR in agricultural systems to AMR 
illness in humans or animals. 
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 Evidence Gaps 
 
• There is no continuous, systematic, national surveillance of AMR in animals and their 
products in developing countries. Surveillance of animals and their products is 
usually not integrated with AMR surveillance in human hospitals and the community.  
• There is no global standardisation for AMR surveillance. The Clinical and Laboratory 
Standards Institute in the US and EU do not agree on key aspects of measuring 
AMR, and the introduction of molecular techniques may further complicate 
comparisons (Vernet et al., 2014).  
• Current technologies for AMR surveillance can be expensive and complicated. 
Molecular diagnostics have the potential to allow rapid detection of resistance and 
information technology could help in reporting and analysing data and therefore 
should be supported. 
• There is no synthesis of existing studies on agriculture associated AMR that would 
provide an overview on prevalence, trends, and variation by farming system, species 
and country. A systematic literature review could summarise and synthesise the 
considerable information available in the published and grey literature. 
• The existing studies on AMR in animals, animal products and animal environments 
often exhibit methodological weaknesses. It would be useful to have guidelines and 
checklists for study quality such as are available for other types of epidemiological 
study. 
• There is limited understanding of the sources of AMR in animal agriculture and the 
relative importance of different sources. This information is needed to target scarce 
resources to where they can be most useful. Comparative molecular epidemiology 
studies of human, animal, food and environmental isolates could shed light on this.  
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SECTION 4 
Health and economic impacts of livestock- and 
fisheries-linked AMR in developing world 
 
 
Evidence 
Information on the health and economic impacts of livestock and fisheries related 
AMR in developing countries is lacking. This is because there is little and weak 
information on how much AMR illness in animals or humans is the result of the use of 
antimicrobials in agriculture. 
 
The previous section summarises the reasonable evidence that despite a lack of good, 
nationally representative data on presence or levels of AMR pathogens in agriculture, AMR 
pathogens are commonly found in agricultural environments, animals and food 
products in developing countries. These could and likely do contribute significantly to 
diseases in humans caused by the same organism. However, these studies do not 
provide information on the origin of AMR in pathogens, so it is not known to what 
extent the presence of AMR in agriculture systems is due to agricultural use of 
antimicrobials. Pathogens can show AMR because: 
 
• They are naturally resistant to antimicrobials. 
• They have been exposed to antimicrobials and developed resistance due to selection 
pressure. 
• They have acquired resistance factors from other bacteria exposed to antimicrobials 
as the result of transfer of resistance conferring genes, often by plasmids. 
 
Natural resistance is considered of minor importance (CDC, 2014) so pathogens in animals 
and their products are mostly likely to develop resistance as a result of exposure to 
antibiotics through these different pathways: 
 
1. Antibiotics directly given to the animals by injection, or as food/water additives to 
treat disease, prevent illness or promote growth (important). 
2. Antibiotics in the environment resulting from antibiotics given to other animals and 
then passed in animal faeces and urine, or from discarded feed or contaminated 
water (probably important). 
3. Antibiotics in the environment resulting from antibiotics used to treat humans or 
companion animals/pets (the latter is probably of minor importance in developing 
countries) and then passed in faeces or urine to contaminate the environment. 
4. Antibiotics in effluents from antimicrobial production (this pathway may be important 
in some countries). 
5. Antibiotics used in plant production (especially fruit trees) or deliberately added to 
food as a preservative (these are probably minor pathways).  
So if an AMR pathogen is found in an animal population, even assuming the pathogen 
developed resistance in that animal population, we do not know which of five exposure 
pathways was relevant. We do not have national estimates of how much veterinary and 
human antibiotics are used in the five pathways listed above, (although we suspect 
some are more important than others), making it difficult to assess the relative 
importance of these sources of exposure in creating resistance. Moreover, when we 
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 find an AMR pathogen in an animal population we do not know whether the resistance was 
generated in the animal population studied or acquired from other animal populations, 
people, or the environment. : 
 
Because of these complications, there is little evidence to inform the extent to which 
AMR infections in people in developing countries are acquired from animals, animal 
products or agro-food environments.  
 
There is some evidence that suggests agricultural use of antibiotics may not have very 
important human health impacts in developing countries: 
 
• Most experts agree that use of antibiotics in human medicine is by far the major 
cause of antibiotic resistance in people (Aarestrop, 2005; Olivier et al., 2010; CDC, 
2014). 
• AMR pathogens are found in livestock that are never given antibiotic treatments e.g. 
backyard chicken and scavenging pigs, suggesting livestock have acquired infection 
from people or from exposure to antibiotics in human excreta (Onyango et al., 2014). 
• In a recent survey, chief veterinary officers reported African countries used an 
average 418 tonnes of antibiotics in agriculture each year (Grace et al., in press). 
This is less than half the amount used by the average OECD country (864 tonnes per 
year) (van Boeckel et al., 2015) suggesting antimicrobial use in some African 
countries is not excessive compared to use in OECD agriculture. 
• The main human health threats from drug resistance are: malaria; tuberculosis; 
streptococcus pneumonia; gram negative infections (ESBL Klebsiella pneumonia and 
E. coli infections) and MRSA (Vernet et al., 2014). Veterinary drug use is only likely 
to contribute directly to ESBL gram negative bacterial infections and MSRA, and the 
extent of its contribution to AMR in these pathogens is not known. 
 
Other evidence suggests agricultural use of antibiotics can have important negative health 
impacts in poor countries: 
 
• In developed countries, industrial agriculture is considered to be the most important 
reservoir for antimicrobial resistant Salmonella and Campylobacter; an increasingly 
important reservoir for MRSA; and, an important but not quantified reservoir for E. 
coli and enterococcal infections (EFSA, 2008; WHO, 2011). Industrial agriculture 
may also be important reservoirs for these pathogens in poor countries. 
• In the first attempt to assemble information on national AMR surveillance, the WHO 
collected data on resistance in infections caused by 9 bacteria of international 
concern (WHO, 2014). Of these 9, we know that non-typhoidal salmonella is usually 
acquired from animals or animal products, and E. coli and S. aureus are sometimes 
acquired from animals and their products (although LA MRSA is believed to be 
mainly acquired from contact with animals). The other 6 bacteria of concern are 
primarily problems of medical use of antibiotics. 
• In developed countries, agriculture is the primary user of antimicrobials in terms of 
total quantities; much agricultural use results in sub-therapeutic exposures for 
bacteria; drugs of every important clinical class are used; and humans are exposed 
to resistant pathogens via consumption of animal products, and via widespread 
release into the environment (Silbergeld et al., 2008). Some of these factors are 
likely already true for developing countries, and the trends are for developing 
countries to become more similar to developed countries in these respects. 
• Case studies show that drug resistance in human pathogens is associated with 
animal pathogens in developing countries. For example, samples from gentamicin-
resistant urinary tract infections and faecal E. coli isolates from humans and food 
animal sources in China showed that 84% of human samples and 76% of animal 
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samples contained the same gene for gentamicin resistance (Ho et al., 2010). It is 
now theorized, from molecular and epidemiological tracking, that the resistance 
determinants found in salmonella outbreaks (strain DT104) in humans and animals in 
Europe and the United States likely originated in aquaculture farms of the Far East 
and the 1992 multiresistant Vibrio cholerae epidemic in Latin America was linked to 
the acquisition of antibiotic-resistant bacteria arising from heavy antibiotic use in the 
shrimp industry of Ecuador (Marshall & Levy, 2011). 
 
Although it is not possible to quantify the impacts of agriculture associated AMR, they are 
potentially high. Antimicrobial-resistant infections currently claim at least 50,000 lives each 
year in Europe and the US (Laxminarayan et al., 2013) and some estimate that drug-
resistant infections will cause 10 million extra deaths a year and cost the global economy up 
to $100 trillion by 2050 (Review on Antimicrobial Resistance, 2014), with most impacts due 
to E. coli, malaria and tuberculosis (of these, only E. coli resistance could be linked to 
agricultural use). Reliable estimates of the true burden of AMR infections in developing 
countries do not exist. In India, nearly 60,000 infants die each year from antibiotic-resistant 
infections (Laxminarayan et al., 2013). If even a small proportion of these cases are due to 
agricultural use of antibiotics, the overall health burden would be significant. 
 
The potential health and economic impacts of agriculture linked AMR in developing countries 
are: 
 
• Human illness from pathogens acquired from direct or indirect contact with animals 
and their waste or through consumption of animal products. 
• Human illness from other pathogens that have acquired copies of a resistance gene 
from antibiotic resistant bacteria acquired from animals or animal products. 
• Animal illness from resistant pathogens. Resistance has developed to virtually all 
anti-infectious drugs used in agriculture (Grasswitz et al., 2004). But while the 
impacts of resistance to trypanocidal and anti-parasitic veterinary drugs in developing 
countries is well documented (Molento et al., 2011), there is less information on the 
impact of AMR infections on animal health. 
• Food products with higher than acceptable antibiotic residues may be rejected. 
Currently this mainly applies to food exported from developing countries, especially 
aquaculture products (as regulations governing residues are rarely enforced in 
domestic markets). For example, antibiotic residues accounted for 28% of EU 
rejections and 20% of US rejections of aquaculture with Vietnam, China, Thailand, 
Bangladesh, and Indonesia most affected (UNIDO, 2011). 
 
In developing countries there is a dual problem of overuse and lack of access to 
veterinary antibiotics. Many more animals die from lack of access to antibiotics than from 
resistant infections.  Meta-reviews of studies from Africa suggest 10% of adult ruminants and 
25% of young ruminants die prematurely each year, most from disease (Otte & Chilonda, 
2002). Others estimate livestock disease in Africa costs from $9 to $35 billion annually 
(Grace et al., in press). Reducing agriculture associated AMR requires reducing the quantity 
and/or improving the quality of antimicrobial use. Interventions aimed at reducing quantity 
may result in higher losses from treatable diseases and net negative impacts on food 
security and poverty. 
 
In developing countries there are related challenges of low livestock productivity and lack of 
animal source foods contributing to 2 billion cases of ‘hidden hunger’ due to micronutrient 
deficiencies. Antibiotics reduce feed requirements and increase weight gain by 2-15% (Hao 
et al., 2014). Because feed is the major cost in industrial systems and profit margins low, 
stopping antibiotics without putting alternatives in place could seriously affect the ability of 
intensive systems to provide cheap, abundant animal source foods.  
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When antimicrobials were banned for growth promotion in Europe, countries saw initial 
increases in antimicrobials used in animal treatment, but it appears with time and 
improvements in husbandry most countries saw sustained decrease in antimicrobial use 
without major impacts in productivity (Marshall & Levy, 2011).  An evaluation in Denmark 
found cost of swine production increased by just 1% after the ban while production declined 
by just 1.4% (WHO, 2002). Still, it has been argued by some in animal husbandry that the 
different situation in the United States means antimicrobial restrictions will result in increased 
morbidity and mortality, projected to cost $1 billion or more over 10 years (Marshall & Levy, 
2011). It is difficult to estimate the likely impacts of a ban in developing countries, but they 
could well be more severe than in Europe. This is because housing, husbandry and 
biosecurity are often poor in developing countries, the environment is often more suited to 
pathogen survival and transmission, and pathogens are more common. 
 
Evidence Gaps 
 
• Antimicrobial usage is not well measured in most developing countries, making it 
difficult to evaluate the relative contributions of veterinary and human antibiotic use 
on resistance in bacterial populations.  
• We do not have systematic, comprehensive data on the prevalence of AMR 
infections in livestock and fish or the costs of these in terms of reduced productivity 
and increased treatment costs. 
• We do not know the contribution of antimicrobial use in food animals in developing 
countries to the development of AMR resistance in infections affecting people. This 
makes it difficult to assess the impact of agriculture-related AMR on human health. 
• We do not understand important aspects of transmission of AMR pathogens or 
genes including the role of animal products, animal contacts, and environmental 
contamination; direction of transmission; and other related factors such as  
• The costs and benefits of antimicrobial use under different systems (intensive, 
extensive), species (cattle, pigs, poultry, fish) and use scenarios (current, reduced, 
increased use) are not known. These should include the costs of lack of access to 
veterinary antibiotics or ability to use in growth promotion. 
• While banning non-therapeutic antimicrobials in Europe has had few negative 
consequences on animal production or welfare, we do not know if this would be the 
case in for developing countries.  
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SECTION 5 
Technical capacity in developing countries to 
assess antibiotic use, antibiotic resistance 
utilising standardised tools in the livestock 
fisheries sub-sector 
 
 
Evidence 
Regulatory capacity is generally good and most countries have policies and regulations in 
place to control the use of antimicrobials in livestock and fish. A survey by the OIE found 
91% of members has legislation covering veterinary medicines, and in most cases 
legislation covered importation, distribution, marketing and use. Around half (51%) of 
countries have banned antimicrobials as growth promoters, while 19% have a partial ban, 
and 30% no ban. Legislation, surveillance systems and bans on growth promotion are all 
trending upwards (Diaz, 2013). There is increasing support for integrated “One Health” 
management of AMR which is articulated in the WHO and OIE strategies (WHO, 2012). 
However, there appears to be lack of communication on legislation: for example, state 
veterinary services who are best placed to understand regulation for veterinary drugs report 
that regulation is in place (OIE, 2012) but WHO offices in the same countries report low or 
no regulation in place for veterinary drugs (Gelband & Delahoym 2014). Moreover, 
dysfunctional health systems (human and veterinary) prevent translation of policy and 
regulation into action. 
 
Surveillance capacity for AMR pathogens in animals, food and agricultural 
environments in developing countries is generally low. Antimicrobial drug resistance is 
usually not monitored in under-resourced countries because they lack surveillance networks, 
laboratory capacity, and appropriate diagnostics (Vernet et al., 2014). In 2014, the WHO 
reported the first attempt to assemble information on national AMR surveillance; however, 
this did not include data on animals, animal products or agricultural environments. A survey 
of African chief veterinary officers (Grace et al., in press) found 66% had no information on 
AMR in animals, 21% considered it was occasional, 4% common and 9% not present in their 
country. Even for surveillance of AMR in humans capacity, in most developing countries is 
low. Moreover, the lack of agreed global standards for AMR surveillance, and discrepancies 
in performance and interpretation of laboratory findings can be such that bacteria considered 
resistant in one laboratory could be classified as susceptible if tested in another laboratory. 
 
Surveillance capacity for antibiotic use in agriculture is low but there are plans to 
improve reporting.  Most developing countries have limited capacity for surveillance of 
antibiotic use in agriculture (Rushton, 2014). Moves are underway to improve this. A study 
by the OIE found that only 27% of members had an official system for collecting quantitative 
data on veterinary medicines, and of those that did around half made the information 
available (Diaz, 2013). Nearly all of these were developed countries. A survey of African 
chief veterinary officers (Grace et al., in press) found just 7 out of 34 respondents (and 54 
countries sent questionnaires) were able to provide quantitative information on use of 
antibiotics in livestock and fish. The OIE is considering how to improve reporting on 
veterinary anti-microbial use, with an initiative to be launched in 2015. 
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 Most countries have limited laboratory capacity. In Africa, a recent report found 
challenges including: lack of external quality assurance; lack of essential reagents; 
inadequate standard operating procedures; noncompliance with internationally recognized 
standards; insufficient capacity for data analysis and dissemination; inadequate training of 
staff performing and interpreting susceptibility tests; lack of national guidelines on 
antimicrobial use; and, weakness of national programs for AMR (WHO, 2013). Similar 
challenges are found in Asia; for example, in Vietnam, data ownership, data quality and 
permissions were flagged up as especial challenges (Wertheim et al., 2013). A common 
problem is that laboratories deal with only human or animal samples. 
 
The capacity to monitor and control sale of veterinary drugs is very weak in most 
countries. A key element of most veterinary medicine legislation requires that antimicrobials 
are used only if prescribed by a veterinary professional. However, most (in some cases 
nearly all) antimicrobials in developing countries are applied without veterinary oversight 
(Grace et al., 2009). Moreover, the high numbers of animals, few veterinarians and the non-
viability of private veterinary practice in many countries imply a prescription-only system with 
direct veterinary oversight is not feasible in the foreseeable future. Even when veterinary 
oversight is present, veterinarians may not have sufficient information or incentives to 
ensure that drug use is rational. 
 
The problem of veterinary drug control needs to be assessed in the context of control of 
medical drugs. In many developing countries, human antibiotic use is relatively uncontrolled, 
and most community care is provided by the informal sector (Bloom et al., 2011). Commonly 
used antimicrobials are comparatively inexpensive (often costing 10- to 30-fold less than the 
same drugs in industrialised nations). In addition, western pharmaceutical companies have 
been reported to distribute antibiotics that are no longer effective or not approved in Europe 
or North America to developing nations (Davies & Davies, 2010).  Most low and middle 
income countries report poor enforcement of antibiotic use policy and when human drugs 
cannot be well controlled, it is unlikely that veterinary drugs will be.  
 
The capacity to monitor and control the use of veterinary drugs is also weak. A 
literature review of vet drug use in developing countries (annex 1) shows: drugs are widely 
used by intensive farmers and less so by smallholders; vaccines and preventative 
treatments are under-used; and, that drug use is often irrational due to lack of proper 
diagnosis or information on correct treatments. To give two examples: in one commune in 
Vietnam, 100% of the large-scale farmers and 60% of small-scale farmers made diagnoses 
and treatments and 60% of them made treatments themselves (using 45 antibiotics readily 
available from agricultural input suppliers. In another example from West Africa, farmers 
reported that 25% of cattle fall sick each year with trypanosomosis and that 90% of sick 
animals were treated, mostly by farmers. Diagnosis and dosage were reasonably accurate 
but 15% of observed treatments were under-dosed (Grace et al., 2009). New approaches 
are needed to improve the performance of human and animal health markets, particularly in 
meeting the needs of the poor. This cannot be achieved by simply importing regulatory 
frameworks and approaches from the advanced market economies (Bloom et al., 2011). 
 
Evidence Gaps 
 
• The lack of comprehensive, systematic, repeated, integrated surveillance systems for 
AMR that cover hospitals, communities, animals, food products and agro-food 
environments is a major gap that will be difficult to fill.  
• The lack of quantified information on veterinary and medical drug use is a major gap, 
as this would allow a rapid screening for countries most at risk for agriculture-related 
AMR. In many countries this information could be easily obtained as antimicrobials 
are imported. 
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• The lack of laboratory capacity is a long-standing problem in developing countries. 
Much effort and expense has been spent on improving capacity, and best 
approaches exist. 
• The lack of harmonised approaches for assessing and reporting AMR is an important 
gap, which would not be difficult to address in countries where AMR is actively 
underway. 
• Given these global coordination issues, there is a role for a binding international legal 
framework to encompass the issues of drug access, conservation and innovation.  
• The weak ability to control the sale and use of human and veterinary antimicrobials in 
developing (and some developed countries) is a major gap that will be difficult to 
overcome. 
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 SECTION 6 
Key drivers of antimicrobial resistance in 
livestock and fisheries production in the 
developing world 
 
 
Evidence  
The key driver of agriculture-related AMR is the quantity and quality of use of 
antimicrobials in livestock production and aquaculture. The key driver of 
antimicrobial use is profitability.  While small amounts of antibiotics are used in crop 
cultivation and forestry, and for treating companion and work animals, in developing 
countries most non-medical use of antimicrobials is almost certainly in livestock and farmed 
fish production. Moreover, it is likely that most veterinary use is in intensive production rather 
than pastoralist or smallholder systems. Antimicrobials are used because they save money 
by treating and preventing disease and by promoting growth. We don't have accurate 
information on antibiotic use in developing countries but several hundred thousand tons are 
probably used, and in many countries agricultural use probably exceeds medical use (Annex 
2). 
 
The underlying driver for antimicrobial use and development of AMR is the livestock 
and aquaculture revolutions: China, Brazil and India are hotspots. This in turn is driven 
by population increases, urbanisation, improving economic conditions and globalisation. 
Based on livestock intensification, China, Brazil and India are current hotspots, and future 
hotspots with fastest growth of the intensive livestock sector in Myanmar, Indonesia, Nigeria, 
Peru and Vietnam (Van Boeckel et al. 2015). This estimated: 
 
• Total consumption in the livestock sector in 2010 was 63,151 tons 
• Global antimicrobial consumption will rise by 67% by 2030 to 105,596 tons 
• The greatest increase (doubling) will be in the BRICS (Brazil, Russia, India, China 
and South Africa) 
• China’s livestock industry by itself could soon be consuming almost one third of 
world’s available antibiotics 
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Figure 1 Global antimicrobial use in food animals  (mg per 10km pixel) 
 
from Van Boeckel et al., 2015 
 
In terms of quantity, intensive swine and cattle production are the most important users 
and poultry and fish are apparently minor (<10% each of total use) (MR, 2014). However, 
these estimates are based on market reports, which, although global, are probably more 
representative of developed countries (Annex 3). Indeed, OECD data suggests poultry use 
may be more important than market reports suggest (Grave, 2010). Although the total 
quantities of antibiotics employed in aquaculture are estimated to be smaller than those 
used in land animal husbandry, there is much greater use of antibiotic families that are also 
used in human medicine (Marshall & Levy, 2011). Extensive and smallholder production 
appear to use relatively small amounts of antibiotics, and most is used for treating sick 
animals rather than disease prevention or growth promotion. Intensive production often 
operates on narrow margins, so the savings from use of antibiotics are important for 
profitability. Moreover, intensive systems require more antibiotics as animals are kept in high 
numbers and density. Most organic production requires that antibiotics should not be used.  
 
Quantities of antimicrobials used reflect by size, intensification, and governance of 
the livestock and fish sector: China, India, Vietnam, Thailand, Brazil, Mexico and 
Indonesia may be hotspots. China is the world’s biggest poultry meat, egg and pork 
producer. Brazil, India, Mexico and South Africa are important developing country poultry 
producers and Brazil, Mexico, Vietnam and Indonesia important pork producers. In Latin 
America, >90% of pork and poultry is produced intensively, in E Asia 70-80%, in SE Asia 50-
60%, in Africa 40% in S Asia, 20% (Herrero et al., 2013). Thailand has an unusually high 
level of intensive production and of antimicrobial use in agriculture. Most (86%) global 
aquaculture is in Asia with 62% in China. Antibiotics are said not to be used widely in the 
low-density fish farming in lakes and reservoirs that predominates, but are a problem in 
production of high value shrimp, eel and turtle (Jiang, 2000).  Chile is the second largest 
producer of farmed salmon and the only important developing country producer. It uses 
around 300 tons of antibiotics: in contrast, the largest salmon producer, Norway, uses less 
than 1 ton (relying instead on vaccination and husbandry measures to control diseases) 
(Annex 2). Other developing countries with important aquaculture sectors are India, Viet 
Nam, Indonesia, Bangladesh, Egypt, Myanmar, Philippines and Brazil. Antibiotic residues 
are a common problem with fish products exported from Vietnam, China, Thailand 
Bangladesh, and Indonesia most affected (UNIDO, 2011). Anecdotally, livestock sector 
governance is low in most of Asia and most of sub Saharan Africa and somewhat higher in 
South Africa and Latin America. 
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 The quality of antimicrobial use is also important:  
 
• Not using the antimicrobials most essential for human health in agriculture (critically 
important list) would slow resistance to these antimicrobials. 
• Using antimicrobials that are also used in human medicine for growth promotion is 
especially conducive to AMR because exposure of many animals to low dosages 
makes resistance more likely to emerge.  
• The practices of treating all animals in a group if one falls ill (metaphylaxis) and of 
treating animals when they are exposed to conditions that make them likely to fall ill 
(prophylaxis) increases the amount of antimicrobials used and as such would 
encourage resistance. However, if only treating sick animals results in more serious 
and frequent illnesses, prophylaxis and metaphylaxis may reduce the total amount of 
antimicrobial used. 
 
Enabling factors  
While quantity and quality of antimicrobial use in agriculture are the proximate drivers of 
agriculture related AMR, there are other factors, which influence development of AMR. 
These include: 
 
• Lack of awareness and concern over antibiotic use: Despite heightened 
awareness in high-income countries and recognition that antibiotic resistance is a 
global problem, the issue is still not on the agenda for most low-income countries and 
some middle-income countries For example, a donor report of major health 
accomplishments in recent years, “resistance” figures prominently in discussions of 
malaria and tuberculosis but is not mentioned at all in relation to common bacterial 
infections (Gelband & Delahoy, 2014). A review of research on AMR enteric bacteria 
in east Africa, reported that research progress on AMR was slow despite the 
importance of antibiotic purchase in health budgets. Moreover, just 24% of studies 
focused on animal or animal product AMR (Omulo et al., 2015). Many veterinarians 
and others involved in food production do not believe that antimicrobial use in 
animals has extensive negative health impacts in people (McEwen, 2001). 
• Lack of information: Developing countries lack information on the presence and 
prevalence of AMR in animals and their products and of the health impacts and cost 
of AMR illness in people and animals. 
• Fake and substandard drugs: There is much concern over counterfeit3 and 
substandard drugs in animal health care, but insufficient data to understand its 
importance. Some counterfeits contain no active ingredients, and these will not lead 
to drug resistance (although they will lead to treatment failure). Counterfeits and 
substandard products, which contain active ingredient at a lower level, will increase 
the chance of resistance developing. There is no comprehensive information on 
fake/substandard veterinary drugs. According to IFAH estimates, the value of the 
official market for veterinary drugs in Africa runs around $400 million a year and the 
trade in sub-standard and non-registered drugs is just as large. Others consider that 
parts of the pharmaceutical industry have incentives to over-emphasize the problem 
of fake and substandard drugs in order to increase markets for their products. 
Farmers frequently complain that products are ineffective, when the problem is 
actually resistant pathogens, misdiagnosis or under-dosage (Grace, 2009). Few 
empirical studies have been carried out and these have mixed results, some finding 
that drugs thought to be substandard were effective (Asmare et al., 2005; Chaka et 
al., 2009); others that drugs had much less than the specified amount of active 
3 WHO defines spurious/falsely-labeled/falsified/counterfeit (SFFC) medicines as medicines that are 
deliberately and fraudulently mislabeled with respect to identity and/or source while substandard 
medicines are pharmaceutical products that do not meet their quality standards and specifications as a 
result of negligence, error or counterfeiting. 
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ingredients (Grasswitz et al., 2004). Even in human medicine, data is insufficient to 
estimate the extent of the problem or its impact on human health, although an often-
quoted estimate is 10% of the global supply is counterfeit (Newton et al., 2010). 
• Poor integration between human and animal health sectors: At international 
level, there is good collaboration between WHO, OIE and FAO in the area of AMR. 
However, in developing countries (and many developed) data on antibiotic use in 
human health care and in agriculture are not systematically collected or shared. 
• Lack of alternatives to antibiotic use: European countries were able to impose a 
ban on the use of growth promoters without excessive negative impact on 
productivity, profitability, animal health or welfare. The feed industry developed 
alternative growth promoters and good practices were adopted to ensure healthy 
herds and flocks. This level of resilience to such bans may not exist among farmers 
in developing countries where such a ban could lead to the use of (poor quality) 
antimicrobials obtained on the black market – exacerbating the problem – or else (or 
as well as) a considerable increase in disease, with consequent mortality and 
morbidity losses. 
 
Evidence Gaps 
 
• We don’t have good information on the current production losses in animal 
agriculture caused by disease and the extent to which these could be averted 
through better use of antimicrobials or their alternatives. 
• Alternatives to using antimicrobials for growth promotion have been successful in 
Europe but their practicability and affordability in developing countries are not well 
understood. 
• There have been considerable investments in disease control options such as 
vaccines, vector control and resistant breeds in developing countries but these have 
not been evaluated from a perspective of reducing veterinary drug use.  
• The prevalence and composition of substandard and counterfeit drugs is not well 
known nor the impacts on treatment failure and fostering resistance. 
• The level of resilience of livestock farmers in developing countries to bans or 
restricted access to antimicrobials. 
• We know policy and regulation alone is unlikely to improve use of vet drugs but the 
options for improving the use of vet drugs in agriculture and their effectiveness, 
feasibility and affordability are not well understood.  
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 SECTION 7 
Modalities of reducing antibiotic use and levels 
of resistance 
 
 
Evidence 
There is broad consensus on what is required to manage AMR in human and animal health. 
These include: 
 
• Reduce need for antibiotics by improving public and animal health (immunization, 
infection control, sanitation, housing and environment).  
• Change incentives for prescribing antibiotics and sales made without a prescription.  
• Change incentives to speed the discovery of new antimicrobials. 
• Reduce environmental contamination with antibiotics from agricultural, hospital and 
community use and manufacture. 
• Develop global, integrated policies covering the use of antibiotics. 
• Phase out antibiotic use for growth promotion and non-therapeutic use in agriculture.  
 
Rational drug use 
A wide range of interventions using educational, managerial, regulatory and 
economic approaches to improve drug use has been studied in human health and 
much has been learned about success factors (Aranda & Mazzotti, 2013). For example, 
the OIE and veterinary professional societies have developed guidelines on judicious 
veterinary drug use and Denmark has put significant limits on the ability of veterinarians to 
profit from the sale of antimicrobials in food production (McEwen, 2001). In developing 
countries, most animal antimicrobial use is probably without veterinary oversight and there 
are additional challenges to improving use. However, approaches shown to improve drug 
use by informal providers would be relevant. A review of 70 interventions found that training 
was the most common approach but was relatively ineffective. However, if combined with 
strategies to change market conditions (by changing incentives and accountability 
environment) better success was achieved (Shah et al., 2010). 
 
Governance of antimicrobial use 
There is consensus that antimicrobial use requires oversight, and that medical and 
veterinary use needs to be considered holistically. Tools for improving governance include 
lists of critical drugs for human and veterinary use, prescription requirements and guidelines 
(e.g. stopping medically important antibiotics in agriculture, cascade systems, guidelines for 
off-label use), and guidelines for monitoring antimicrobial use and AMR. So far, there has 
been little success implementing these in livestock and fish production in developing 
countries (but also relatively little investments in implementing these). 
 
The OIE sees empowerment of veterinarians and restriction of antimicrobial prescription to 
the veterinary profession as key to better governance of veterinary antimicrobials. However, 
private veterinary practice has not been able to establish or provide services on significant 
scale in most developing countries. Private vets are usually too costly for smallholders, and 
intensive industrial agriculture firms often prefer to employ veterinarians directly, which 
makes them less independent.  Recent models based on franchises may be more viable but 
are still under evaluation (http://www.farmafrica.org/kenya/sidai).  ‘Agro-vets’, that is small 
shops run by 6 month – 2 year trained professionals have been successful but are not in line 
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with current OIE policy (Lewis, 2001). Community animal health workers have proven very 
effective (Leyland et al., 2014), and may be politically acceptable, but can be expensive to 
train and oversee. Public veterinary services often lack resources to support CAHWs while 
private veterinarians often oppose them as actual or potential competitors. All these private 
veterinary models are prone to perverse incentives as practitioners’ earnings are tied to 
dispensing.  Only one study has investigated rational drug use by farmers: this found 
farmers in west Africa were mainly responsible for buying and using antibiotics and that 
providing simple information on correct drug use could improve use and reduce the 
proportion of under-dosages, which is an important driver for AMR emergence (Grace et al., 
2008). 
 
Alternatives to antimicrobials in animal agriculture 
European countries stopped use of medically important antibiotics and growth promoters in 
agriculture. This was followed by a widespread change in farming practices and a reduction 
in AMR in bacteria important to human health being found in farm animals. This natural 
experiment showed routine antibiotics are not necessary to produce healthy animals, 
provided their living conditions, rearing and foods are improved and curative antibiotics are 
used for clinical illness. However, production without routine antibiotics can increase costs 
and management efforts. On the other hand, these management efforts often lead to better 
housing conditions and improved animal welfare.  A caveat is that the benefits of 
antimicrobials for growth promotion seem higher under poor hygiene conditions (McEwen, 
2001). These are characteristic of intensive livestock production in developing countries, and 
consequently will increase the difficulty of developing country producers from shifting away 
from reliance on non-therapeutic antimicrobials.  
 
Nonetheless, there are many promising innovations, which could support profitable and 
productive agriculture with less use of antimicrobials. These include:  
 
• Non antibiotic growth promoters such as In feed enzymes, competitive exclusion 
products and probiotics/prebiotics  
• Other animal health technologies, such as vaccines, vector control, phages, and 
disinfectants – many of which are underused in developing countries  
• Diagnostics to improve drug selection and identify AMR pathogens 
• Management and biosecurity innovations such as all-in-all-out systems, pathogen 
free systems, reducing stocking density and improving waste management  
• Genetically disease resistant animals and avoidance of monocultures of genetically 
similar animals. 
 
Some of these interventions may also improve animal welfare (e.g. reducing stocking 
density) and reduce environmental externalities of animal agriculture. More radical 
suggestions are to decrease the amount of animal source food consumed or shift from 
intensive to extensive or organic animal production. 
 
Dual problem of overuse and lack of access 
In rich countries, underuse of antibiotics and consequently a reduction of preventable deaths 
from infection in livestock have been greatly reduced. In poor countries, many more animals 
die from lack of access to antibiotics than from resistant infections. In addition, the OIE 
estimates that 25% of livestock production is lost due to disease globally (OIE, 2015). This 
represents at least 60 million tonnes of meat and 150 million tonnes of milk with a value of 
approximately USD 300 billion per year. In this context, measures to restrict the use of 
antibiotics in agriculture could have un-intended consequences on Income derived from 
livestock, livelihoods and nutrition. 
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 Evidence Gaps 
 
• Tackling agriculture linked AMR:  While the principles of managing AMR are well 
accepted, there is very little evidence on how this can be practically achieved in the 
context of developing country agriculture.  
• Rational drug use: There has been very little research into better management of 
veterinary antimicrobial use, but some of the lessons learned from medical 
interventions probably apply. 
• Animal health service delivery is sub-optimal in most developing countries and new 
approaches need to be developed and evaluated. 
• There are many promising innovations which could support profitable and productive 
agriculture with less use of antimicrobials but further development and adaptation is 
needed before they can be expected to adequately substitute for current uses of 
antibiotics in animal agriculture in developing countries. 
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SECTION 8 
Recommended research priorities 
 
 
A number of recent reviews clearly show that use of antibiotics in food animals 
(particularly nontherapeutic use) can affect the health of people on farms and, via the 
food chain, the health of consumers and communities. Evaluations following the bans in 
Europe on nontherapeutic use of antimicrobials show bans are feasible and affordable, at 
least, in the European context. However, the contribution of agricultural antimicrobial 
use to the overall burden of human AMR infections and the health benefits of bans on 
AMR in humans are less clear. AMR to human pathogens has overall continued to 
increase despite the bans. 
 
Moreover, in developing countries, there is a dearth of evidence on most aspects of 
agricultural related AMR. This includes; the use of antimicrobials in agriculture, the impacts 
of this use on human and animal health, the acceptability and feasibility of stricter control on 
antibiotic use in agriculture, and the costs and benefits of stricter control. The latter should 
take into account trades offs between overuse and lack of access to antimicrobial drugs, and 
between the health impacts of AMR attributable to antibiotic use and nutritional problems 
attributable to insufficient intake of animal source foods. Given the current failure to control 
human and veterinary drugs, it is likely that bans would be difficult to implement. And given 
the problems of lack of access to veterinary drugs and insufficient intake of animal source 
foods, it is possible that restricting the use of veterinary drugs could have additional negative 
impacts, unique to developing countries. 
 
At the same time, AMR is intrinsically a global problem that can only be managed at supra-
national scale and by addressing all of the important uses of antimicrobials. The current 
strong momentum to take action on AMR provides an opportunity to address the problem 
globally and comprehensively, addressing medical and veterinary use. This should be done 
in an evidence-based way which includes filling knowledge gaps, careful piloting of 
interventions, and rigorous evaluation of success and failure. In this context, some of the key 
research questions for better managing agricultural use of antimicrobials in developing 
countries, based on this report, but also the literature, are: 
 
How big a problem? 
 
• What is the current evidence on agricultural AMR in developing countries in terms of 
prevalence, trends, and variation by farming system, species and country? 
• How much antimicrobials are used in agriculture (absolutely and relatively to medical 
use) and how does this vary by species, system and country? 
• What is the contribution of antimicrobial use in food animals in developing countries 
to the development of AMR resistance in infections affecting people?  
 
How is it created? 
 
• To what degree and in what directions are there transfer of antimicrobial resistance 
(i.e. between plants, animals, humans and environmental organisms)? What are the 
risk factors for transmission? 
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 • What is the rate of development of medically important bacterial resistance in food-
producing animals, in relation to duration of exposure to and concentration of 
antimicrobial and including the resistance selection potential of antimicrobials 
permitted minimum residue levels? 
• What is the effect of current food processing and distribution on the emergence and 
spread of AMR? 
• What is the effect of environmental contamination with antimicrobials from veterinary, 
medical and agronomy use and manufacture on the emergence and spread of AMR? 
• How common are fake and counterfeit veterinary drugs, and what is their contribution 
to the development of AMR? 
• What are the incentives for producers to use antimicrobials and how do animal health 
systems restrict or increase access to veterinary drugs?  
What should be done about it? 
 
• What are the costs and benefits of antimicrobial use under different systems 
(intensive, extensive), species (cattle, pigs, poultry, fish) and use scenarios (current, 
reduced, increased use)? These should include the costs of lack of access to 
veterinary antibiotics and inability to use in growth promotion. 
• What is the effect of cessation of use of antimicrobials on the prevalence and 
persistence of resistant bacterial in food-producing animals and their immediate 
environment?  
• Given the lack of firm information on many aspects of antimicrobial use in developing 
country agriculture and its health impacts, but the strong possibility this could cause 
irreversible harm, what actions are appropriate and which require further evidence?  
What are promising approaches for managing agricultural related AMR? 
 
• How can comprehensive, systematic, repeated, integrated surveillance systems for 
AMR that cover hospitals, communities, animals, food products and agro-food 
environments be developed? 
• What are the threshold levels of resistance that are of public health concern? How 
can these be monitored and what are the actions when thresholds are exceeded? 
• What new approaches to animal health service delivery can address the dual 
burdens of lack of antimicrobial access and antimicrobial over use? 
• What animal health and husbandry innovations would support profitable and 
productive agriculture with less use of antimicrobials and how can these be extended 
to developing countries? 
• How can the management and technology innovations that support animal 
production without use of growth promoters in Europe be extended to developing 
countries? 
• What is the potential role of consumer demand, high value markets and private 
standards in reducing antimicrobial use in developing country agriculture? 
• How can rational drug use principles be extended to agricultural use of antibiotics in 
developing countries?  
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 Annex 1 Literature review on veterinary drug use in developing countries 
 
Selection of keywords used: veterinary drug use (‘in Africa’ and ‘in Asia’); rational drug use; 
knowledge attitude practices and (‘specific disease’); improper use of veterinary drugs   
 
Databases searched: Google Scholar, PubMed 
 
Citation Study 
location 
Sample 
size 
Animal 
Disease 
Drug/Use/Frequency Notes 
Addah et al 
(2009) 
 
 
Ghana 
 
Sample 
size 
n=100 
70 farmers 
and 30 
herdsman 
Ticks and 
helminths 
Acarides use (submitted by 
participants for inspection): 
…66% used Cyprin 
…10% used Hexiprametrin 
…6% used Amitraz 
…5% used Deadly backline 
…3% used herbal preparations 
…10% used unorthodox chemicals 
 
52% of respondents used acaricides at 
levels below recommended dosages 
 
Administration of acarides 
…80% on-the-spot hand dressing 
…15% dipping/washing 
…5% pour-on 
 
Antihelminthics use (submitted by 
participants for inspection): 
…7% used Albendazole (2.5 w/v) 
…16% used Albendazole (25mg) 
…11% used Albenol (2.5%) 
…15% used Albevet (10%) 
…15% used Analgon (25mg) 
…30% used BenvetGR (2500mg) 
…16% used Albenol (25mg) 
 
72% of respondents used 
antihelminthics at levels below 
recommended dosages 
 
Administration (who) of both drugs 
…50% pastoral herdsman (I think this 
could mean self-administered) 
…30% livestock farmers (I think this 
could mean self-administered) 
…11% community livestock workers 
…9% veterinary personnel 
 
By label examination of both drugs 
…75% of acaricides used by 
participants had not exceeded the 
expiry date 
…53% of antihelminthics used by 
participants had not exceeded expiry 
date 
 
More on their 
methods: “Livestock 
farmers submitted 
acaricides and 
anthelminthes (in 
their original 
containers) used for 
treating their 
animals for 
inspection. Info from 
drug labels was 
documented: trade 
name, country of 
origin, manufacturer, 
active ingredients, 
expiry date, 
language of 
instruction/ 
inscription, 
recommended 
dosage, mode of 
administration and 
official certifying 
agency. The 
containers used to 
measure each 
parasiticide and 
water for dilution 
when indicated, 
were also used to 
determine whether 
the product was 
used as 
recommended  on 
the label, over-
dosed or under-
dosed. In some 
instances, 
respondents were 
asked to 
demonstrate how 
they used either 
parasiticide. Tick 
and helminths 
control practices of 
farmers were also 
observed during 
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Citation Study 
location 
Sample 
size 
Animal 
Disease 
Drug/Use/Frequency Notes 
Source of both drugs 
…41% from private veterinary shops 
…32% from village markets 
…25% from district MoFA vet clinics 
…2% chemical peddlers 
visits.” 
Bardosh et 
al (2013)  
Uganda 
 
Sample 
size  
n=495 
livestock 
keepers 
Trypanoso
mosis 
(AAT) 
Types of drugs used: 
…35% - pyrethroids 
…25% - amitraz 
…40% - could not name product 
 
Of those who used acaricides 
…21% claimed to spray for both ticks 
and tsetse flies 
…79% sprayed only for ticks 
“This was explained by the low tsetse 
challenge in the area, beliefs about 
disease risk (that acquiring human 
sleeping sickness was unlikely), the 
higher cost of pyrethroids and a belief 
that acaricides could only kill tsetse 
flies if the fly came into direct contact 
with the insecticide during spraying.” 
 
17% did not use acaricides at all 
 
In the rainy season, cattle were 
sprayed 
…15.7% weekly 
…21.5% fortnightly 
…2.8% every 3 weeks 
…24.5% every month 
…18.7% irregular intervals 
“Interviews and 
focus groups 
showed that 
adhering to a 
prescribed spraying 
interval was a 
challenge for 
farmers due to 
competing interests 
and demands on 
time and money. 
Tick presence rather 
than a prescribed 
time period dictated 
the spraying 
interval.” 
Catley et al 
(2002) 
Kenya Bovine 
trypanoso
mosis 
No % listed, only ranking 
“Herders used an integrated approach 
to control bovine trypanosomosis 
involving up to 10 control methods” 
 
Modern methods listed by informants 
for controlling bovine trypanosomosis 
(rank order):  
…Trypanocides 
…Pour ons 
…Dips 
 
Indigenous methods listed by 
informants for controlling bovine 
trypanosomosis:   
…movement of cattle away from 
tsetse-infested areas 
…bush clearance to reduce contact 
with tsetse 
…dung fires in kraals 
…blood letting 
…herbal remedies 
 
 
Ezenduka Nigeria – Poultry Most commonly used antibiotics From the 
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 Citation Study 
location 
Sample 
size 
Animal 
Disease 
Drug/Use/Frequency Notes 
et al (2011) Enugu 
State 
n=25 layer 
farmers 
diseases …100% oxytetracycline 
…72% macrolides 
…52% aminoglycosides 
…12% quinolones 
…8% sulphonamides 
…8% nitrofurans 
…(no% ) beta-lactams and ionophores 
are least used  
 
conclusion, but no 
supporting data that 
I could find reported 
in article: “It is also 
very obvious that 
poultry farmers 
(without the 
consultations of a 
Veterinarian) in the 
study area do not 
adhere to 
withdrawal periods 
of antimicrobial 
drugs; most times, 
farmers do not even 
bother reading the 
manufacturer’s 
instructions before 
the use of a drug.” 
 
Grace et al 
(2009) 
Burkina 
Faso, Mali 
and 
Guinea 
 
n=895 
farmers 
 
 
Cattle 
trypanoso
mosis 
(AAT) 
An average of 3.5 preventive 
strategies per farmer were used, 
across all three countries  
 
Treatment 
“Most frequently cited drug of first 
choice for AAT treatment was DIM and 
followed by ISMM. Most popular drug 
of second choice (or fallback) was 
ISMM.” 
…89.6% of farmers used trypanocides 
to treat cattle they believe are sick with 
AAT, either as sole treatment or 
alongside non-trypanocidal modern 
drugs 
…5.4% used non-trypanocidal drugs 
only 
 
Treatment (who) 
…41.8% of cases of sick cattle were 
treated by community members other 
than the owner or herder 
…31.1% of cases were treated by the 
farmer or his herder 
…13.9% of cases were treated by vets 
 
Preventive methods 
…49.7% used trypanocidal drugs, 
either ISMM or repeated doses of DIM 
during risk periods 
…32.5% avoided high-risk areas by 
watering cattle at pumps instead of 
water-courses and grazing in areas 
where flies are fewer 
…7.4% kept trypanotolerant cattle 
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Citation Study 
location 
Sample 
size 
Animal 
Disease 
Drug/Use/Frequency Notes 
<1% of farmers reported unsafe 
practices such as giving ISMM and 
DIM at the same time or mixing 
trypanocides with antibiotics and giving 
as injections. 
 
Heffernan 
et al (2011) 
India 
 
n=601 
(414 
urban and 
187 peri-
urban/rura
l livestock 
keepers) 
Vaccines, 
in general 
Vaccination behavior (n=184) 
…47% foot-and-mouth disease 
(cattle/buffalo)  
…21% hemorrhagic septicaemia 
(buffalo)  
…14% fowl pox (chicken)  
…17% Newcastle disease (chicken)  
…0.5% rabies (horse)  
…0.5% tetanus (goat)  
…1% typhoid (chicken)  
 
43% of farmers reported having 
vaccinated any of their animals during 
the past 12 months. Only 30% of these 
farmers named a livestock disease for 
which a vaccine exists, i.e. 
Hemorrhagic Septicaemia (HS), Foot 
and Mouth Disease (FMD), Newcastle 
disease (NCD), Rabies, Tetanus, Fowl 
Pox and Fowl Cholera. 
“Vaccination was often confused with 
treatment for other diseases such as 
bloat or intestinal parasites…Urban 
producers had the highest level of 
nonreporting.” 
From the 
conclusion, “Among 
participants, the 
adoption of livestock 
vaccination was, on 
a macro-level, 
deeply embedded 
within the existing 
social system and 
on a more micro-
level, related to very 
specific knowledge 
frames. Contrary to 
conventional 
wisdom, the ‘ability 
to pay’ for 
vaccination, did not 
appear to be the 
primary inhibitor to 
effective vaccination 
coverage.” 
Kisinza et 
al (2011) 
Tanzania 
 
Interviews 
with 
agriculture 
and public 
health 
officers, 
total 
number of 
interviews 
was not 
reported 
Malaria 
among 
cattle and 
poultry  
No percentages, just lists 
 
Insecticides used for livestock 
spraying:  
…Stelladone (Chlorfenvinphos 300g/L) 
…Dominex (Alphacypermethrin 10%) 
…Ectomin (Cypermethrin)  
…Sevin dust (Cabaryl 75g/Kg).  
 
Others included Tactic, Triatix, 
Norotrax and Amitix all of which 
contain Amitraz 12.5%, for cattle only. 
Dipping or spraying of animals was 
reportedly done 2 to 4 times a month. 
 
 
Liebenehm 
et al (2011) 
Mali and 
Burkina 
Faso 
 
Results 
from an 
impact 
evaluation 
of 
program 
AAT Practices of farmers – program 
participants   
…55.92% administer drug by 
themselves     
…71.09% use DIM as the first choice      
…2.37% correctly dose DIM      
…5.69% correctly dilute DIM      
…10.9% use ISMM as the first choice       
…4.27% correctly dose ISMM      
…11.37% correctly dilute ISMM      
From the 
conclusion, four key 
elements were 
identified for 
enhancing the 
adoption of RDU 
principles by 
farmers:   
 
1. Create 
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 Citation Study 
location 
Sample 
size 
Animal 
Disease 
Drug/Use/Frequency Notes 
introducin
g RDU 
principles 
to 
smallholde
r farmers 
 
…74.41% correctly identify the 
injection site   
…65.4% purchase trypanocides at 
formal market  
 
Practices of farmers – non-participants 
…39.39% administer drug by 
themselves     
…73.42% use DIM as the first choice      
…1.68%correctly dose DIM      
…1.35% correctly dilute DIM      
…8.42% use ISMM as the first choice       
…0.34% correctly dose ISMM      
…2.02% correctly dilute ISMM      
…68.35% correctly identify the 
injection site      
…45.12% purchase trypanocides at 
formal market   
 
‘knowledge 
champions’ through 
training, who can be 
used as mediators 
in village networks 
given the right 
incentive scheme. 
2. Improving 
farmers’ veterinary 
knowledge leads to 
productivity increase 
3. Mass media are 
effective tools to 
create awareness, 
and to transmit 
knowledge. 
4. Boundary 
spanning 
approaches 
between farmers 
and researchers 
such as participatory 
methods increase 
acceptance 
 
Majekodun
mi et al 
(2010) 
Nigeria – 
Jos 
plateau 
 
Sample 
size  
n=30 
villages 
Trypanoso
mosis 
(AAT) 
(all based on % of villages, not 
households as far as I could tell) 
Trypanocides used for treatment: 
…50% diminazine only 
…3.3% isometamidium only 
…3.3% mixture of diminazine and 
isometamidium 
…36.7% used both drugs 
…6.7% did not know names of drugs 
 
Preparation: 
…43.3% diluted using 
bottled/packaged water  
…26.6% used well/stream water 
…23.2% used water from both types of 
sources  
…46.7% water from natural sources 
was boiled before use 
…33.3% used the correct amt of water 
per sachet of drug 
 
Point of purchase for drugs, % of 
villages:  
…66.7% Agro-vet  
…3.3% Vet  
…3.3% Nat’l Vet Research Institute  
…23.3% Both vets and agro-vets  
…3.3% Both NVRI and agro-vets 
(3.3%) 
 
Most farmers treated animals 
 
Why curative 
treatment was 
preferred to 
prevention? 
- Most effective way 
to control 
trypanosomiasis 
(73.3%) 
- Easiest (13.3);  
- Only available 
strategy (10.0);  
- Cheapest (3.3.) 
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Citation Study 
location 
Sample 
size 
Animal 
Disease 
Drug/Use/Frequency Notes 
themselves and all dosed animals 
incorrectly. 
 
Moyo & 
Masika 
(2009) 
South 
Africa – 
Eastern 
Cape 
Province 
 
Sample 
size  
n=59 
cattle 
farming 
household
s 
Tick-borne 
diseases 
 
Most 
commonly 
reported 
ones in the 
study area: 
anaplasmo
sis 
(89.9%), 
babesiosis 
(55.9%) 
and 
ehrlichiosis 
(16.9%) 
In the study area, “the gov’t provides a 
dipping service where acaricide Triatix 
500 TR (Amitraz 50%) is provided for 
use in communal dip tanks, once a 
week in summer and fortnightly during 
winter. The community selects one 
member of the community to mix the 
acaricide in the dip tank. Dipping of 
cattle is not compulsory and small 
ruminants like goats are not dipped.” 
 
95% of farmers claimed the acaricide 
(dip wash) was not effective in killing 
ticks. As a result,  
…30.5% relied only on gov’t dipping 
service 
…23.0% complemented the dipping 
service by buying own acaricides 
…45.8% used alternative methods 
(ethno-vet practices) 
 
Of those who used commercial 
acaricides:  
…22% applied Triatix 125 (Amitraz 
12.5%) when spraying  
…1.7% used pouricides 
 
Nonga et 
al (2009) 
Tanzania 
 
n=20 
smallscale 
broiler 
chicken 
farmers 
Poultry 
diseases 
 
Most 
commonly 
reported 
diseases 
which 
necessitate
d use of 
antibiotics 
(in order 
from most 
to least 
reported): 
-
Coccidiosis 
-Infectious 
coryza 
-Fowl 
typhoid 
-Yolk sac 
infection 
-Newcastle 
disease 
-Gumboro 
-Helminths 
Common antimicrobials used in broiler 
chickens as reported by farmers 
(frequency of use - %) 
…90% Tetracycline (CTC & OTC) 
…85% Amprolium 
…85% Sulphonamides 
…55% Trimethoprim 
…25% Neomycin 
…15% Flumequine 
 
90% reported frequent use of 
antibiotics 
75% reported use of antibiotics for 
treatment and prevention of diseases 
65% reported use of antibiotics as a 
growth promoter 
25% reported use of antibiotics as a 
treatment for chickens when sick  
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 Citation Study 
location 
Sample 
size 
Animal 
Disease 
Drug/Use/Frequency Notes 
 
Olatoye 
and Basiru 
2013 
Nigeria 
n=20 
farmers 
Antibiotics 
in 
aquacultur
e 
production 
90% engaged in routine administration 
of antibiotics to prevent fish diseases 
65% administered drugs routinely to 
prevent disease outbreak or mortality 
losses without engaging the services 
of a vet for disease diagnosis or 
treatment 
100% administered several antibiotics 
ranging from oxytetracycline, procaine, 
penicillin G, Malachite Green and 
enrofloxacin to their fish for disease 
prevention, treatment, and productivity 
performance 
 
73% administered oxytetracycline both 
to the fish stocks and to the fish feed 
 
85.5% were neither aware of the 
withdrawal period for antibiotics nor 
the potential hazards of antibiotic 
residue in humans 
 
 
From the 
discussion: “Most of 
the drugs used by 
the aquaculture 
farmers interviewed 
were not specifically 
indicated for fish, 
extra-label use of 
mostly poultry and 
human antibiotic 
preparations was 
observed to be 
commonly 
practiced…This 
study revealed that 
most farmers in 
Ibadan have low 
level of education 
and have 
unrestricted access 
to antibiotics (over 
the counter), 
thereby engaging in 
self-medication of 
their stocks as a 
routine practice 
without proper 
diagnosis and not 
observing of 
withdrawal period. 
High proportions 
(75%) of the 
respondents in this 
study were not 
knowledgeable on 
the deposition and 
the public health 
implication of the 
residues in fish 
meat.”  
Oluwole et 
al (2012)  
Nigeria - 
Ibadan 
 
Sample 
size 
n=84 
farmers  
--66 
commerci
al, 
9 breeder 
stock, and 
9 mixed 
stock 
Newcastle 
disease 
Avian 
Influenza 
Vaccinate against ND: 100% 
Vaccinate against AI: 16.7% 
 
For NDV, 38.1% of farmers complied 
w/vaccination schedule provided by 
hatchery source of their chickens; 
51.2%  vaccinated their birds at strictly 
4-6 wks interval and would not use 
hatchery 
schedule; 10.7% used partly hatchery 
schedule strictly combined w/lab 
advice to vaccinate at variable 
intervals 
 
Omeiza et Nigeria Poultry Chloramphenicol (CAP) use  
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Citation Study 
location 
Sample 
size 
Animal 
Disease 
Drug/Use/Frequency Notes 
al (2012)  
n=105 
poultry 
farmers 
diseases 
 
 
…20% administered the veterinary 
CAP preparation 
…14.3% administered the human CAP 
preparation to poultry 
 
Administration (who) 
…11.4% reported CAP was 
administered by vet or paravet 
…36.2% reported CAP was 
administered by untrained personnel 
 
Administration (mode) 
…13.3% reported the mode of 
administration was vet prescription 
…18.1% reported the mode of 
administration was manufacturer’s 
prescription 
…37.1% reported the mod of 
administration was self 
Peters et al 
(2012)  
Kenya –  
Kakamega 
and 
Machakos  
 
Sample 
size 
n=558 
farmers 
Cattle 
diseases, 
general 
Did not report % overall, only 
disaggregated by location 
 
In Kakamega 
67% used vaccines to prevent 
diseases in cattle  
…28.1% to prevent ECF 
…17.5% to prevent Blackquarter 
…7.5% to prevent FMD 
…6.2% to prevent lumpy skin disease 
…5.5% to prevent RVF 
…4.8% to prevent anthrax 
 
In Machakos 
69.0% used vaccines to prevent 
diseases in cattle  
…13.4% to prevent ECF 
…10% to prevent Blackquarter 
…12.4% to prevent FMD 
…8.6% to prevent lumpy skin disease 
…5.3% to prevent RVF 
…20.1% to prevent anthrax 
 
Detail beyond % of farmers who had 
treated for these diseases was not 
specified so vaccine use is all that is 
reported here in the lit review.  
Veterinarians (not 
specified whether 
this was private or 
gov’t based) were 
the most commonly 
reported person 
vaccinating cattle 
(72% in Kakamega 
and 86% in 
Machakos) and 
tended to be 
organized by the 
gov’t and 
compulsory when 
disease outbreaks 
occurred.  
 
 
Diseases 
in small 
ruminants, 
general 
In Kakamega 
…23% used vaccines to prevent 
diseases in small ruminants 
…24% used vaccines to prevent 
CCPP 
 
In Machakos 
…46% used vaccines to prevent 
diseases in small ruminants 
…51% used vaccines to prevent 
Veterinarians were 
the most commonly 
reported person 
vaccinating small 
ruminants, but about 
25% of farmers 
reported 
administrating 
disease treatments 
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 Citation Study 
location 
Sample 
size 
Animal 
Disease 
Drug/Use/Frequency Notes 
CCPP 
Diseases 
in 
chickens, 
general 
39.3% used vaccines to prevent 
diseases in chickens in Kakamega 
17.5% used vaccines to prevent 
diseases in chickens in Machakos 
 
In Kakamega, the 
paravet was the 
most common 
administrator 
(37.1%) followed by 
farmer (26.5), then 
vet (14.6). In 
Machakos, it was 
the farmer (25.6), 
followed by vet 
(24.4), then paravet 
(6.7) 
Saddiqi et 
al (2012) 
Pakistan 
 
Key 
responden
t 
interviews 
with key 
responden
ts:    
vet officers 
(n=15)  
vet 
assistants 
(n=51) 
traditional 
practitione
rs (n=24) 
small and 
large 
scale 
sheep/goa
t farmers 
(n=60) 
Gastrointes
tinal worms 
in sheep 
and goats 
 
 
Use 
…76% used modern anthelmintics 
…20% used a mix of both traditional 
and modern 
…4% used traditional anthelmintics 
…50% of traditional practitioners used 
both modern and traditional 
anthelmintics 
 
Preferences 
…58% preferred class II (LEV) as the 
modern drug of choice 
…14% preferred class I (BZ) 
…28% preferred a combination of 
these two classes 
 
“Most of respondents preferred Nilzan 
plus (levamisole) and Systamex 
(oxfendazole, a benzimidazole). The 
preference was for those drugs, which 
initiated diarrhoea, such as levamisole, 
believing that the diarrhoea helped to 
expel the worms. The majority of 
respondents did not rotate the 
dewormers (a recommendation to 
reduce the development 
of parasite resistance against the 
drugs) neither did veterinary officers 
and veterinary assistants. They 
changed the dewormer only after one 
drug showed poor results.” 
 
Administration 
50% used deworming after every 6 
months 
20% used deworming every 3 months 
30% used when indicated  
----- 
58% of all respondents administered 
anthelmintics in diluted form 
60% of veterinary officers were found 
using diluted drugs, to the satisfaction 
of clients who suspected that 
“Veterinary officers 
and assistants and 
owners preferred to 
use modern 
anthelmintics. 
Traditional 
practitioners and 
farmers used 
indigenous 
homeopathic 
preparations, which 
according to them 
had good results 
(visual observation 
for the removal of 
worms). Herbal or 
homeopathic 
dewormers are 
available from 
veterinary 
pharmacies 
(“Canizole”, against 
intestinal worms and 
flukes of sheep and 
horses; “Deworming 
plus” against 
intestinal worms, 
flukes and external 
parasites of sheep 
and horses; “Granil” 
a combination of 
dewormer, minerals, 
vitamins and active 
enzymes) although 
these products are 
not registered in the 
country.” 
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Citation Study 
location 
Sample 
size 
Animal 
Disease 
Drug/Use/Frequency Notes 
administrating the drug in pure form 
(per recommendations) may lead to 
toxicity 
 
Wyatt and 
Grace 
(2013a and 
2013b) 
Kenya and 
Tanzania 
 
Sample 
size 
In Kenya, 
n=316 
farmers; in 
Tanzania, 
n=456 
farmers 
Newcastle 
disease 
In Tanzania 
29% treated the chicken if suspected 
to have ND 
- 50% of these HH used 
traditional medicine 
42% of farmers reported having ever 
used the NDV 
 
Of those who had used the NDV 
…54% reported the NDV was 
administered by a community 
vaccinator 
…20% reported it was administered by 
an extension workers 
…15% reported it was administered by 
a vet 
…12% reported it was self-
administered  
…5% reported it was administered by 
another HH member 
 
In Kenya 
64% treated the chicken if suspected 
to have ND 
- 66% of these HH used 
traditional medicine 
34% of farmers reported having ever 
used the NDV 
 
Of those who had used the NDV 
…93% reported the NDV was 
administered by a village based ag 
advisor 
…4% reported it was administered by 
community vaccinator 
…4% reported it was self-administered  
 
 
 References available on request   
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 Annex 2 Reports on antibiotic use 
Country Income 
2010 
Poultry 
x1000 
Sheep & 
Goats 
Pigs Cattle AB ton Ab 
G/VLU 
Year Source 
Iceland High 218 480,284 40,016 73,781 1 6.25 2010 EMA 
Norway High 4,412 2,375,791 850,383 874,535 6 3.98 2010 EMA 
Latvia High 4,829 83,900 376,500 378,200 7 10.59 2010 EMA 
Estonia High 1,824 80,400 365,100 234,700 8 17.14 2010 EMA 
Slovenia High 3,052 168,004 415,230 472,878 8 11.54 2010 EMA 
Sweden High 7,808 564,900 1,519,900 1,536,700 14 5.80 2010 EMA 
New 
Zealand 
High 13,841 32,657,881 335,114 3,600,000 57 7.95 2010 MPI 
Cyprus High 4,330 435,212 463,932 55,522 57 152.81 2011 EMA 
Switzerlan
d 
High 8,966 512,249 1,583,290 1,602,820 58 22.92 2010 EMA 
Austria High 16,338 429,800 3,134,000 2,013,280 62 16.37 2010 EMA 
Czech 
Republic 
High 25,067 228,409 1,907,990 1,328,930 71 27.77 2010 EMA 
Ireland High 15,760 4,651,700 1,518,300 6,606,600 96 12.02 2010 EMA 
Denmark High 14,546 159,626 13,173,100 1,571,050 119 14.30 2010 DANMA
P 
Portugal High 46,500 3,393,000 2,324,900 1,391,100 181 53.90 2010 EMA 
Hungary High 40,284 1,281,000 3,247,000 700,000 206 72.17 2010 EMA 
Belgium High 34,830 142,000 6,430,000 2,593,000 299 48.46 2010 EMA 
United 
Kingdom 
High 170,245 31,084,500 4,423,000 9,901,000 456 26.94 2010 EMA 
Netherlan
ds 
High 103,438 1,544,000 12,252,000 650 461 63.02 2010 EMA 
Poland High 131,866 380,385 14,865,300 5,723,940 479 33.00 2011 EMA 
Australia High 86,447 72,585,500 2,289,290 26,733,000 644 17.89 2009-
2010 
APVMA 
Japan High 286,003 27,000 9,800,000 4,376,000 656 54.04 2010 MAFF 
Rep Korea High 158,215 263,000 9,880,630 3,351,390 843 85.19 2010 QIA 
France High 172,741 9,325,580 14,531,900 19,620,900 997 33.74 2011 EMA 
Spain High 138,905 21,485,400 25,342,600 6,075,100 1,746 78.35 2010 EMA 
Italy High 154,000 8,973,600 9,157,100 6,447,000 1,928 143.21 2010 EMA 
Germany High 128,899 2,238,476 26,509,000 12,809,500 2,002 72.60 2010 EMA 
USA High 2,351,088 8,658,000 64,887,000 93,881,200 13,542 89.86 2011 FDA 
Kenya Low 30,398 23,191,000 347,400 17,862,900 15 0.73    Paper 
Philippine
s 
LM 170,227 4,207,700 13,397,800 5,841,300 1,244 84.84   Paper 
Thailand LM 261,421 423,416 7,623,730 8,120,650 12,417 851.12   Paper 
China LM 5,921,786 284,727,767 476,237,000 107,400,29
5 
200,00
0 
461.67   Paper 
Lithuania UM 9,309 67,200 928,200 759,400 16 12.09 2010 EMA 
Bulgaria UM 17,354 1,761,072 729,798 571,311 46 35.93 2011 EMA 
Russ. UM 403,793 21,988,200 17,231,000 20,681,840 47 1.32   Paper 
Chile UM 75,979 4,394,350 2,706,150 3,900,000 450 69.74   Paper 
Iran UM 511,600 79,700,000   9,150,000 1,000 44.97   Paper 
South 
Africa 
UM 126,535 30,775,850 1,594,490 13,731,000 1,500 79.49   Paper 
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Grams of antibiotics used in the production of one livestock unit 
 
 0 to 10 grams per 
TLU 
11-40 grams per 
TLU 
41-100 grams per TLU >200 
grams per 
TLU 
High income 
(2010) 
Norway, Iceland, 
New Zealand, 
Sweden 
Australia, Ireland, 
UK, Switzerland, 
France 
Japan, Germany, Spain, 
Hungary, Netherlands, 
Korea, USA, 
Italy, 
Cyprus 
Developing 
(2010) 
Russian 
Federation, Kenya 
Lithuania, Bulgaria Iran, South Africa, 
Philippines, Chile (in fish) 
China, 
Thailand 
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 Annex 3 Market Report Summary: 2013  
Executive Summary 
According to market research, the global animal antimicrobials market was valued at just 
over $3 billion in 2013 and is expected to reach $4 billion by 2018. The market is highly 
consolidated and dominated by a small number of North American and European firms. 
Challenges include the increased demand for regulatory bans and concerns over animal 
production and welfare while growing livestock numbers and increasing demand for animal 
protein are driving increases in demand for antimicrobials. The current focus in developed 
markets in North America and Europe but this is expected to shift to high growth markets in 
Asia and other developing countries. Globally, there is a shortage of new antibiotics in the 
pipeline of major pharmaceutical companies owing to low returns on investment on the 
animal antimicrobial products.  
 
By product type, tetracyclines continue to remain the leading category, accounting for 
around half the market in 2015 and with strong growth potential. The penicillins and 
sulfonamides segments are also large markets with shares of 14.9% and 10.7%, 
respectively, in 2013. The pig sector dominates the global animal antimicrobials and 
antibiotics market, accounting for a market share of approximately one quarter and growing 
fast. This segment is also poised to grow at a higher rate during the forecast period.  
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